Descripción de la empresa
Reviva Pharmaceuticals Holdings, Inc. operates as a biopharmaceutical entity dedicated to the discovery, development, and commercialization of next-generation therapeutics designed to address unmet medical needs within the central nervous system, respiratory, inflammatory, and cardiometabolic disease domains. The company functions within the broader Healthcare sector, specifically navigating the highly regulated and capital-intensive Biotechnology industry where research and development cycles are critical for value creation. With a market capitalization of $9.12M and an employee base of 14, the firm presents as a micro-cap enterprise with a very limited operational footprint. These valuation figures indicate that the company is priced as a speculative growth vehicle rather than an established revenue generator, reflecting the typical risk profile associated with early-stage biotechnology firms that prioritize pipeline advancement over current profitability.
Salud financiera
The financial performance of Reviva Pharmaceuticals Holdings, Inc. is characterized by significant losses, with a Net Income (TTM) of $-19,864,902 and no reported Revenue (TTM) or EBITDA figures available in the dataset. The substantial negative net income relative to the absence of revenue highlights a cost structure heavily weighted toward research, development, and operational overhead expenses that have not yet been offset by sales. The company generated Free Cash Flow of $-17,137,860, indicating a consistent outflow of cash required to sustain its operations and development activities. This negative cash flow position suggests limited financial flexibility, as the company must rely on external capital sources to fund its ongoing burn rate. The company reports Gross Margin, Operating Margin, and Profit Margin figures all at 0.0%, which is indicative of a company that has either not yet generated commercial sales or operates in a phase where revenue recognition does not yet align with standard margin calculations due to lack of revenue. On the balance sheet, the firm holds $14.44M in Cash against $406,875 in Debt, resulting in a Debt to Equity ratio of 4.71. Despite the high debt-to-equity figure, the absolute level of debt is relatively low compared to cash reserves, suggesting a conservative leverage position regarding absolute debt obligations, though the equity base is likely small. The Current Ratio stands at 2.08, signaling that the company possesses sufficient current assets to cover its short-term liabilities with a ratio greater than two. Return on Equity is reported at -420.0% and Return on Assets at -80.3%, metrics that reveal significant capital inefficiency and the challenges management faces in generating positive returns on the invested equity and assets during this developmental stage.
Evaluación de valoración
Valuation multiples for Reviva Pharmaceuticals Holdings, Inc. present a complex picture due to the lack of earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.86. The negative forward P/E ratio implies that the market is pricing the stock based on anticipated future profitability or is utilizing a non-standard metric given the current negative earnings trajectory. The Price to Book ratio is 0.48, indicating that the market values the company at less than half of its book value, which often suggests a deep discount or that the asset base does not fully reflect the intangible value of the drug pipeline. Price to Sales and EV/EBITDA metrics are both listed as N/A, rendering these traditional valuation comparisons impossible without revenue data, which forces reliance on price-to-book and cash metrics for assessment. Regarding price action, the stock has traded between a 52-Week High of $23.20 and a 52-Week Low of $0.59. The current trading position relative to this wide range suggests extreme volatility, as the price has fluctuated significantly from its recent peak, though the specific current price is not provided in the source facts to calculate an exact percentage deviation. The Beta is 0.64, which indicates that the stock's price volatility is lower than the broader market benchmark, suggesting less sensitivity to general market movements despite the inherent risks of the biotechnology sector.
Growth & Income
The company reports Revenue Growth (YoY) and Earnings Growth (YoY) as N/A, precluding a direct comparison of earnings growth versus revenue growth rates in this specific reporting period. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue based on the available data points. Reviva Pharmaceuticals Holdings, Inc. does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. As a non-dividend payer, the company's strategy involves reinvesting all available resources, including its cash reserves, directly into its research and development pipeline rather than distributing income to shareholders. This approach is typical for biotechnology firms at this stage of development, where capital is prioritized for advancing clinical trials and securing regulatory approval for new therapeutics. The overall growth and income profile is defined by a complete absence of current profitability and dividend distributions, relying entirely on the potential future success of its product candidates to generate value for investors.